section name header

Indications ⬇

BEERS REMS

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Derm: ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS, cutaneous lupus erythematosus, DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS (TEN).

F and E: hypocalcemia (especially if treatment duration ge.gif3 mo), hypokalemia (especially if treatment duration ge.gif3 mo), hypomagnesemia (especially if treatment duration ge.gif3 mo).

GI: abdominal pain, diarrhea, CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD), flatulence, fundic gland polyps, nausea, vomiting.

GU: acute tubulointerstitial nephritis.

Hemat: vitamin B12 deficiency.

MS: bone fracture.

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS, ANGIOEDEMA, OR ACUTE TUBULOINTERSTITIAL NEPHRITIS), systemic lupus erythematosus.

Interactions ⬆ ⬇

Drug-Drug:

Availability ⬆ ⬇

(Generic available)

Route/Dosage ⬆ ⬇

Hepatic Impairment

US Brand Names ⬆ ⬇

Dexilant

Action ⬆ ⬇

Therapeutic Effects:

Classifications ⬆ ⬇

Therapeutic Classification: antiulcer agents

Pharmacologic Classification: proton pump inhibitors

Pharmacokinetics ⬆ ⬇

Absorption: Well absorbed following oral administration.

Distribution: Unknown.

Protein Binding: 96–99%.

Metabolism/Excretion: Extensively metabolized by the liver, primarily by the CYP2C19 and CYP3A4 isoenzymes; the CYP2C19 isoenzyme exhibits genetic polymorphism (15–20% of Asian patients and 3–5% of Caucasian and Black patients may be poor metabolizers and may have significantly ↑ dexlansoprazole concentrations and an ↑ risk of adverse effects); no active metabolites. No renal elimination.

Half-life: 1–2 hr.

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTEONSETPEAK*DURATION
POunknown1–2 hr (1st); 4–5 hr (2nd)24 hr

*Reflects effects of delayed release capsule.

Patient/Family Teaching ⬆ ⬇

Pronunciation ⬆ ⬇

dex-lan-SOE-pra-zole

Code ⬆

NDC Code*